Reflecting a positive reception in the market, Kestra Medical Technologies Ltd. increased the target haul for its planned IPO from $100 million to between $140 million and $160 million in an S-1 amendment filed Feb. 26. The company will offer 10 million shares at $14 to $16 per share, with the final price to be set the week of Mar. 3, just ahead of the offering date. Read More
After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for its kidney cancer PET imaging agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), granting it a priority review with a PDUFA date of Aug. 27, 2025. Read More
Scientists at the University of Aberdeen developed a new scanner that distinguishes breast tumor material from healthy tissue more accurately than current magnetic resonance imaging (MRI) methods. Read More
The routine use of software to interpret the results of lab-developed tests (LDTs) leaves clinical labs in a complicated spot in 2025 thanks in no small part to an ongoing lawsuit over the U.S. FDA’s final rule for LDTs. Read More
The Clarivate Medtech Trends to Watch in 2024 report noted the resilience of the medtech sector in the face of changing macroeconomic factors and the preparation required to navigate the market’s many complexities. It is likely that 2025 will be no different. Read More
New hires and promotions in the med-tech industry, including: Affluent Medical, Jupiter Endovascular, Nucleus Genomics, Veda Bio, Zimmer Biomet. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Averto, Bracco, Eyenovia, Lucid, Natera, Sphere Fluidics, Zereau. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abanza, Medibeacon, Sway, Visby. Read More
